Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Phase 1 study which included 40 older adults (>56 years) found adverse events were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titres than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial.

Source:

New England Journal of Medicine